The double-edged sword of H19 lncRNA: Insights into cancer therapy

H19 long non-coding RNA (lncRNA) has many functions in cancer. Some studies have reported that H19 acts as an oncogene and is involved in cancer progression by activating epithelial-mesenchymal transition (EMT), the cell cycle and angiogenesis via mechanisms like microRNA (miRNA) sponging – the bind...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2021-03, Vol.500, p.253-262
Main Authors: Shermane Lim, Yun Wei, Xiang, Xiaoqiang, Garg, Manoj, Le, Minh TN, Li-Ann Wong, Andrea, Wang, Lingzhi, Goh, Boon-Cher
Format: Article
Language:English
Subjects:
Angiogenesis
Apoptosis
Cancer
Cancer immunotherapy
Cancer therapeutics
Cancer therapies
Cell cycle
Cell growth
Chemoresistance
Colorectal cancer
Drug development
Epigenetics
Gene expression
H19
Hypoxia
Immunotherapy
Insulin-like growth factors
Long non-coding RNA
Lung cancer
Mesenchyme
Metastasis
Microenvironments
MicroRNAs
miRNA
Musculoskeletal system
Non-coding RNA
Oncogene
p53 Protein
Proteins
RNA-mediated interference
Tumor microenvironment
Tumors
Tumour suppressor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:H19 long non-coding RNA (lncRNA) has many functions in cancer. Some studies have reported that H19 acts as an oncogene and is involved in cancer progression by activating epithelial-mesenchymal transition (EMT), the cell cycle and angiogenesis via mechanisms like microRNA (miRNA) sponging – the binding to and inhibition of miRNA activity. This makes H19 lncRNA a potential target for cancer therapeutics. However, several conflicting studies have also found that H19 suppresses tumour development. In this review, we shed light on the possible reasons for these conflicting findings. We also summarise the current literature on the applications of H19 lncRNA in cancer therapy in many cancers and explore new avenues for future research. This includes the use of H19 in recombinant vectors, chemoresistance, epigenetic regulation, tumour microenvironment alteration and cancer immunotherapy. The relationship between H19 and the master tumour suppressor gene p53 is also explored. In most studies, H19 knockdown via RNA interference (RNAi) or epigenetic silencing inhibits cancer development. Thus, H19 lncRNA could be a promising target for the development of cancer therapeutics. This warrants further investigations into its translational research to improve cancer therapy outcomes.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2020.11.006